A Decentralized, Randomized Phase 2 Efficacy and Safety Study of Nirmatrelvir/Ritonavir in Adults With Long COVID.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05668091 |
Recruitment Status :
Active, not recruiting
First Posted : December 29, 2022
Last Update Posted : March 5, 2024
|
Sponsor:
Harlan M Krumholz
Collaborator:
Pfizer
Information provided by (Responsible Party):
Harlan M Krumholz, Yale University
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Active, not recruiting |
---|---|
Estimated Primary Completion Date : | April 9, 2024 |
Estimated Study Completion Date : | August 27, 2024 |